- Brain Decline, Dementia Common Among Older American Indians
- Stroke, Migraine, Alzheimer’s: Climate Change Will Likely Make Them Worse
- Immunotherapy Before and After Surgery Boosts Lung Cancer Survival
- Cream Cheese From Aldi, Hy-Vee Stores Recalled Due to Salmonella Risk
- Seeing Your Doctors Via Zoom? What’s Behind Them Matters
- Mediterranean Diet Could Be a Stress-Buster, Study Finds
- PTSD Triples Odds for Teeth Grinding, Study Finds
- Dreams Might Help You Process Bad Experiences
- Lymphoma: Know Your Treatment Options
- FDA Approves First Self-Test Collection Kit for HPV
Movantik Approved for Constipation From Opioids
Movantik (naloxegol) has been approved by the U.S. Food and Drug Administration to treat opioid-induced constipation, the agency said Tuesday.
Opioids are powerful painkillers that commonly cause constipation. Movantik’s safety and effectiveness to treat the problem were evaluated in two clinical studies involving 1,352 people who had taken opioids for at least four weeks for non-cancer related pain.
The most common side effects of Movantik were abdominal pain, diarrhea, headache and excessive gas, the FDA said in a news release.
Manufacturer AstraZeneca will be required to do an additional study to further evaluate the drug’s cardiovascular safety, the agency added.
AstraZeneca is based in Wilmington, Del.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.